10/21/2014 - 10:05 AM EST - Critical Outcome Technologies Inc. : announced today that it recently executed a material transfer agreement with Dr. Jeffery Myers, MD, PhD, FACS of The University of Texas MD Anderson Cancer Center for the continued evaluation of COTI-2 in the potential treatment of patients with head and neck squamous cell cancer. Critical Outcome Technologies Inc.
shares V.COT are trading unchanged at $0.27.
